Showing results (101-110 of 115) with videos related to
Sort By:
Pageof 12
Oncogene|April 28, 2026
Rapid activation of ARF6 after RAF inhibition augments BRAFV600E and promotes therapy resistanceJunhua Wang, Yinshen Wee, Thomas Jacob, et al.Molecular Cancer Therapeutics|November 6, 2023
Genetic Silencing of AKT Induces Melanoma Cell Death via mTOR SuppressionGennie L Parkman, Tursun Turapov, David A Kircher, et al.Cell Reports|April 22, 2014
Isolation and molecular characterization of circulating melanoma cellsXi Luo, Devarati Mitra, Ryan J Sullivan, et al.Nature|November 6, 2012
An ultraviolet-radiation-independent pathway to melanoma carcinogenesis in the red hair/fair skin backgroundDevarati Mitra, Xi Luo, Ann Morgan, et al.Cancer Research|September 16, 2022
Transposon Mutagenesis Reveals RBMS3 Silencing as a Promoter of Malignant Progression of BRAFV600E-Driven Lung TumorigenesisAria Vaishnavi, Joseph Juan, Maebh Jacob, et al.Nature Medicine|March 6, 2019
Protective autophagy elicited by RAF→MEK→ERK inhibition suggests a treatment strategy for RAS-driven cancersConan G Kinsey, Soledad A Camolotto, Amelie M Boespflug, et al.Nature Medicine|March 29, 2019
Publisher Correction: Protective autophagy elicited by RAF→MEK→ERK inhibition suggests a treatment strategy for RAS-driven cancersConan G Kinsey, Soledad A Camolotto, Amelie M Boespflug, et al.Biorxiv : the Preprint Server for Biology|December 25, 2025
Genetic Drivers of Sensitivity or Resistance to RAS(ON) Multi-Selective Inhibitors in NRAS-Mutated MelanomaMona Foth, Wontak Kim, Kayla T O'Toole, et al.Cancer Research|May 22, 2026
Genetic Drivers of Sensitivity or Resistance to RAS(ON) Multi-Selective Inhibitors in NRAS-Mutated MelanomaMona Foth, Wontak Kim, Kayla O'Toole, et al.Nature Genetics|February 10, 2015
The Hippo effector YAP promotes resistance to RAF- and MEK-targeted cancer therapiesLuping Lin, Amit J Sabnis, Elton Chan, et al.Pageof 12